In Marc Beardslee opinion, Intercept Pharmaceuticals, Inc. is a biopharmaceutical firm based in the United States that was created in 2002. The primary emphasis of the firm is on the development of synthetic bile acid analogs as therapies for a variety of chronic liver illnesses. Because it is one of the world's fastest-growing biotech businesses, its stock price is rapidly increasing. Here are some of the reasons why you should purchase this stock. Let's look at its product pipeline and how it may improve your health.
New executives were recently appointed by the firm. Intercept has appointed M. Michelle Berrey as President of Research and Development, in addition to Mark Pruzanski as CEO. Linda Richardson will be the company's Chief Commercial Officer, while Andrew Saik will be its Chief Financial Officer. Intercept Pharmaceuticals has been in business for almost two decades, and its success story demonstrates its commitment to continuous innovation. Dr. Robert Liew, a former physician who has been involved with the firm's research and development, was recently promoted as part of a series of key hiring made by the corporation.
Marc Beardslee pointed out that, Obeticholic acid, a therapy for primary biliary cholangitis, is one of the company's commercial assets. The FDA has authorized this medication for both primary biliary cholangitis and nonalcoholic steatohepatitis. This is encouraging news since obeticholic acid has the potential to be a large yearly hit in the US market. However, the company's success was hindered by a series of setbacks. Intercept is one of many high-profile firms that have declared bankruptcy.
According to Marc Beardslee, The FDA authorized Ocaliva in 2016 for the treatment of PBC, an inflammatory liver disease caused by a bile duct abnormality. Intercept's saliva is a strong bile duct-targeting farnesoid X receptor agonist. The company's primary product is Ocaliva, which is sold under the brand name Ocaliva. While the FDA continues to evaluate the effectiveness of this medication, the business is working on a Phase III study for a longer examination.